SILVERARC CAPITAL MANAGEMENT, LLC

Position in XENE — Xenon Pharmaceuticals Inc.

CIK 1816307 BOSTON, MA

Position in XENE

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$11,499,685

+$11,160,126 QoQ

Shares Held

197,759

+1853.9% QoQ

Ownership

0.205%

of shares outstanding

% of Portfolio

1.36%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2021

13 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $784,099,188 across 56 Biotechnology names. XENE ranks #21 (1.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	KALV	KalVista Pharmaceuticals, Inc.	2,876,407	$57,902,072
2	DNTH	Dianthus Therapeutics, Inc. /DE/	654,746	$54,946,284
3	COGT	Cogent Biosciences, Inc.	1,314,189	$50,583,134
4	CELC	Celcuity Inc.	357,903	$40,851,048
5	IMNM	Immunome Inc.	1,850,278	$40,465,579
6	KOD	Kodiak Sciences Inc.	991,930	$37,812,371
7	NUVL	Nuvalent, Inc.	354,914	$36,360,939
8	ABVX	Abivax S.A.	302,530	$33,686,715

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$11,499,685	197,759	+1853.9%	Shares	Sole	2026-05-14
2025-03-31	$339,559	10,121	-84.7%	Shares	Sole	2025-05-14
2024-03-31	$2,845,174	66,090	-59.5%	Shares	Sole	2024-05-15
2023-12-31	$7,515,518	163,168	+202.2%	Shares	Sole	2024-02-14
2023-09-30	$1,844,503	53,996	-45.9%	Shares	Sole	2023-11-13
2023-06-30	$3,840,606	99,756	+3.2%	Shares	Sole	2023-08-14
2023-03-31	$3,458,852	96,643	-61.9%	Shares	Sole	2023-05-15
2022-12-31	$10,001,616	253,655	+3.1%	Shares	Sole	2023-02-14
2022-09-30	$8,880,311	245,992	+5.7%	Shares	Sole	2022-10-28
2022-06-30	$7,076,604	232,630	+130.1%	Shares	Sole	2022-07-25
2022-03-31	$3,090,046	101,081	+1.1%	Shares	Sole	2022-05-13
2021-12-31	$3,124,000	100,000	+414.6%	Shares	Sole	2022-02-14
2021-09-30	$296,920	19,432	—	Shares	Sole	2021-11-15
No filing history on record for this holder in this stock.